Nile Therapeutics Inc.
http://capricor.com/#/home
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nile Therapeutics Inc.
Asia Deal Watch: invoX Builds Novel Pipeline Through $161m F-star Acquisition
F-star's novel bispecific technology attracts Sino Biopharma-affiliated acquisition, Shionogi agreement with GARDP brings antibiotic cefiderocol to 135 countries, deal with WinHealth covering Greater China expands Quoin’s licensing of Netherton syndrome candidate to 60 nations, Kyorin and CellGenTech team up in Fabry disease.
Korean Bio/Healthcare Sector Sees Ample Fund Inflows In 2021
Financing for Korean bioventures and pharma firms remained strong this year amid ample liquidity and strong investor sentiment in the sector. SK Bioscience's IPO was the top fundraiser in 2021, followed by HK inno.N’s offering, while GI Innovation raised the most money from venture capital sources.
AB Science’s Masitinib/Docetaxel Benefits In Advanced Prostate Cancer
AB Science’s top-line results from a Phase III study suggest its lead candidate masitinib may be of benefit when combined with docetaxel chemotherapy in patients with early metastatic castration-resistant prostate cancer.
Finance Watch: Biotech Venture Capital Had Its Biggest Quarter Ever
Private Company Edition: VC mega-rounds boosted the Q1 2021 total. Also, new funds from Versant, The Column Group and Rapha Capital keep cash flowing into biopharma; up to $525m is invested in Exscientia; and Arch Oncology and Boundless Bio raised $105m each, while Forge brought in $120m.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy